CinFina Pharma Presents Positive Phase 1 Study Results in Poster Session for CIN-109 and in Late-Breaking Poster for CIN-110, Demonstrating the Potential of Next-Generation Mechanisms at ObesityWeek® 2024
CinFina Pharma Presents Positive Phase 1 Study Results in Poster Session for CIN-109 and in Late-Breaking Poster for CIN-110.
CinFina Pharma to Present Posters Demonstrating the Potential of New Mechanisms at ObesityWeek® 2024
CinFina Pharma to Present Posters Demonstrating the Potential of New Mechanisms at ObesityWeek® 2024
CinRx Pharma Announces First Study for the Treatment of Obesity
CinRx Pharma announced the first study participant has been dosed in CinFina’s Phase 1 multiple ascending dose (MAD) study of CIN-109.
